News

WOBURN and Weston, Mass., May 6, 2008 – CreaGen Biosciences, Inc. and ProXyChem, LLC announced today that the two companies have entered into an agreement to combine their expertise in offering comprehensive Structure-Based Drug Design (SBDD) and lead optimization services. Drug discovery research is a complex, time-consuming activity that interweaves multiple scientific disciplines on the path to creating new treatments for human diseases. While once virtually the exclusive province of large pharmaceutical companies, large numbers of small pharmaceutical and biopharmaceutical start-ups have entered the drug discovery field. Medicinal Chemistry and SBDD operations require specialized skills and expensive infrastructure, leading many small companies to outsource some or all of these operations. CreaGen and ProXyChem have teamed up to provide their complementary capabilities to client companies as a seamlessly integrated Medicinal Chemistry and SBDD service.